ISU Abxis is at the forefront of developing engineered antibody-based immunotherapies aimed at treating tumors and rare diseases. Their innovative platform focuses on monoclonal antibodies (mAbs) that target specific proteins involved in cancer progression and rare conditions. Notable products in their pipeline include ISU104 (Barecetamab), an anti-ErbB3 mAb designed to inhibit cancer cell growth by blocking the ErbB3 protein, which is often associated with drug resistance in cancer therapies. Additionally, ISU Abxis is advancing ISU304, a modified recombinant Factor IX protein for the prophylactic treatment of Hemophilia B, and ISU305, a biosimilar of Eculizumab for treating Paroxysmal Nocturnal Hemoglobinuria (PNH).

The company is also exploring novel therapeutic approaches, such as combining their antibodies with CAR-NK technology to enhance immune responses against cancer cells. Their use of Probody technology in ABX2001 allows for the activation of pro-cytokines specifically within the tumor microenvironment, promoting anti-tumor activity. Through these advanced technologies, ISU Abxis aims to address significant unmet medical needs in oncology and rare diseases, improving treatment options and patient outcomes.

South Korea

ISU ABXIS is continuously striving to provide better treatment options
for patients suffering from difficult-to-treat diseases based on
Isu’s excellence in biotechnology.

ISU Abxis

Company Details